---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-017501"
form_type: "8-K"
ticker: "IRMD"
cik: "0001325618"
company_name: "IRADIMED CORP"
filed_at: "2023-11-03T23:59:59+00:00"
generated_at: "2026-06-08T22:09:15.535242+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Iradimed reports record Q3 revenue $16.5M, raises FY GAAP EPS guidance to $1.34-$1.37

## Summary
- Q3 revenue $16.5M (+23% YoY); GAAP diluted EPS $0.40 vs $0.27 YoY; non-GAAP diluted EPS $0.43 vs $0.29 YoY.
- Operating income $5.9M, up 43% YoY; ninth consecutive quarterly revenue record led by monitoring business up 40% QoQ.
- Q4 2023 guidance: revenue $16.9M-$17.4M; GAAP EPS $0.35-$0.38; non-GAAP EPS $0.38-$0.41.
- Full-year 2023 guidance raised: revenue $65.0M-$65.5M; GAAP EPS $1.34-$1.37 (up from prior); non-GAAP EPS $1.48-$1.51.
- Cash flow from operations $3.5M in Q3 ($9.6M YTD) vs $2.4M ($7.0M YTD) YoY.

## SEC filing metadata
- accession: 0001558370-23-017501
- form_type: 8-K
- ticker: IRMD
- cik: 0001325618
- company_name: IRADIMED CORP
- filed_at: 2023-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1325618/000155837023017501/0001558370-23-017501-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1325618/000155837023017501/irmd-20231103x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-017501
- JSON: https://secwatch.observer/filing/0001558370-23-017501.json
- Plain text: https://secwatch.observer/filing/0001558370-23-017501.txt

## Key facts
- Earnings Releases
  IRADIMED CORP reported nine months ended September 30, 2023 results: net income $14.0 million, EPS $1.1.
  - Period: nine months ended September 30, 2023
  - Net income: $14.0 million
  - EPS: $1.1
  - Result: reported results
  source text: For the nine months ended September 30, 2023, the Company reported revenue of $48.1 million compared to $38.4 million for the same period of 2022. Net income was $12.7 million, or $0.99 per diluted share, compared to $9.2 million, or $0.72 per diluted share for the same period of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1325618/000155837023017501/0001558370-23-017501-index.htm
- Earnings Releases
  IRADIMED CORP reported nine months ended September 30, 2023 results: net income $14.0 million, EPS $1.1.
  - Period: nine months ended September 30, 2023
  - Net income: $14.0 million
  - EPS: $1.1
  - Result: reported results
  source text: Non-GAAP net income was $14.0 million, or $1.1 per diluted share, for the nine months ended September 30, 2023, and excludes $1.3 million of stock compensation expense, net of tax expense.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1325618/000155837023017501/0001558370-23-017501-index.htm
- Earnings Releases
  IRADIMED CORP reported fourth quarter 2023 results: EPS $0.38 to $0.41. Guidance initiated.
  - Period: fourth quarter 2023
  - EPS: $0.38 to $0.41
  - Guidance: initiated
  - Result: guidance update
  source text: For the fourth quarter of 2023, the Company expects to report revenue of $16.9 million to $17.4 million, GAAP diluted earnings per share of $0.35 to $0.38, and non-GAAP diluted earnings per share of $0.38 to $0.41.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1325618/000155837023017501/0001558370-23-017501-index.htm
- Earnings Releases
  IRADIMED CORP reported third quarter ended September 30, 2023 results: net income $5.5 million, EPS $0.43.
  - Period: third quarter ended September 30, 2023
  - Net income: $5.5 million
  - EPS: $0.43
  - Result: reported results
  source text: For the third quarter ended September 30, 2023, the Company reported over 23% year-over-year revenue growth to $16.5 million compared to $13.4 million for the third quarter of 2022. Net income was $5.1 million, or $0.40 per diluted share, compared to $3.4 million, or $0.27 per diluted share for the third quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1325618/000155837023017501/0001558370-23-017501-index.htm
- Earnings Releases
  IRADIMED CORP reported third quarter ended September 30, 2023 results: net income $5.5 million, EPS $0.43.
  - Period: third quarter ended September 30, 2023
  - Net income: $5.5 million
  - EPS: $0.43
  - Result: reported results
  source text: Non-GAAP net income was $5.5 million, or $0.43 per diluted share, for the quarter ended September 30, 2023, and excludes $0.4 million of stock compensation expense, net of tax expense.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1325618/000155837023017501/0001558370-23-017501-index.htm
- Earnings Releases
  IRADIMED CORP reported full-year 2023 results: EPS $1.48 to $1.51. Guidance raised.
  - Period: full-year 2023
  - EPS: $1.48 to $1.51
  - Guidance: raised
  - Result: guidance update
  source text: For the full-year 2023 financial guidance, the Company now expects to report revenue of $65.0 million to $65.5 million, GAAP diluted earnings per share of $1.34 to $1.37, and non-GAAP diluted earnings per share of $1.48 to $1.51.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1325618/000155837023017501/0001558370-23-017501-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.